577793-67-0

Upstream product

• 577793-66-9 5-ethoxy-2-fluoro-phenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 459-26-7 4-ethoxy-1-fluorobenzene 

Downstream Products

• 577793-68-1 3-(tert-butyl-dimethyl silanyloxy)-5-ethoxy-2-fluoro-benzaldehyde 
• 918810-89-6 3-(tert-Butyldimethylsilyloxy)-5-ethoxy-2-fluorophenylboronic acid 
• 376601-45-5 (4-cyano-phenylamino)-{3-ethoxy-2-fluoro-5-[(R)-tetrahydro-furan-3-yloxy]-phenyl}-acetic acid ethyl ester 
• 906079-97-8 (4-cyano-phenylamino)-[3-ethoxy-2-fluoro-5-(tetrahydro-furan-3-yloxy)-phenyl]-acetic acid ethyl ester 
• 376601-44-4 (4-cyano-phenylamino)-(5-ethoxy-2-fluoro-3-hydroxy-phenyl)-acetic acid ethyl ester 

Relevant academic research and scientific papers

Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial throm